Cargando…

The ambiguous role of FPR1 in immunity and inflammation

Detalles Bibliográficos
Autores principales:	Vacchelli, Erika, Le Naour, Julie, Kroemer, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199809/ https://www.ncbi.nlm.nih.gov/pubmed/32391192 http://dx.doi.org/10.1080/2162402X.2020.1760061

Ejemplares similares

A major genetic accelerator of cancer diagnosis: rs867228 in FPR1
por: Sztupinszki, Zsofia, et al.
Publicado: (2021)

Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer
por: Carbonnier, Vincent, et al.
Publicado: (2023)

No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19
por: Petrazzuolo, Adriana, et al.
Publicado: (2020)

Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis
por: Le Naour, Julie, et al.
Publicado: (2023)

Trial watch: IDO inhibitors in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Trial watch: TLR3 agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin
por: Pol, Jonathan G., et al.
Publicado: (2020)

A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
por: Le Naour, Julie, et al.
Publicado: (2022)

Improved Swiss-rolling method for histological analyses of colon tissue
por: Le Naour, Julie, et al.
Publicado: (2022)

Poly(ADP-ribose) polymerase-1 and its ambiguous role in cellular life and death
por: Castedo, Maria, et al.
Publicado: (2023)

Trial watch: Toll-like receptor ligands in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2023)

FPR1 is the plague receptor on host immune cells
por: Osei-Owusu, Patrick, et al.
Publicado: (2019)

FPR Ligands
por: Liu, Ying, et al.
Publicado: (2013)

Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2
por: Zhuang, Youwen, et al.
Publicado: (2022)

Beneficial autoimmunity and maladaptive inflammation shape epidemiological links between cancer and immune-inflammatory diseases
por: Pol, Jonathan, et al.
Publicado: (2022)

Critical role of FPR1 in splenocyte migration into brain to worsen inflammation and ischemic brain injury in mice
por: Li, Jun, et al.
Publicado: (2022)

Cell Death Signaling and Anticancer Therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2011)

A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice
por: Lévesque, Sarah, et al.
Publicado: (2019)

The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis
por: Snapkov, Igor, et al.
Publicado: (2016)

Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2–Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages
por: Marutani, Takayuki, et al.
Publicado: (2021)

Cerebral ambiguity
por: Baracchini, Claudio
Publicado: (2014)

Immune infiltrate in cancer
por: Stoll, Gautier, et al.
Publicado: (2015)

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
por: Enot, David P., et al.
Publicado: (2018)

Microenvironment involved in FPR1 expression by human glioblastomas
por: Boer, J. C., et al.
Publicado: (2015)

Inflammation and Cancer: Role of Annexin A1 and FPR2/ALX in Proliferation and Metastasis in Human Laryngeal Squamous Cell Carcinoma
por: Gastardelo, Thaís Santana, et al.
Publicado: (2014)

Identification and validation of FPR1, FPR2, IL17RA and TLR7 as immunogenic cell death related genes in osteoarthritis
por: Ren, Tingting, et al.
Publicado: (2023)

Leveraging FPR2 Agonists to Resolve Inflammation and Improve Outcomes Following Myocardial Infarction
por: Koenig, Andrew L., et al.
Publicado: (2021)

Trial watch: intratumoral immunotherapy
por: Humeau, Juliette, et al.
Publicado: (2021)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

Neutrophil Infiltration of the Colon Is Independent of the FPR1 yet FPR1 Deficient Mice Show Differential Susceptibilities to Acute Versus Chronic Induced Colitis
por: Farooq, Shukkur M., et al.
Publicado: (2012)

The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability
por: Petri, Marcelo H., et al.
Publicado: (2015)

Decreased Placental FPR2 in Early Pregnancies That Later Developed Small-For-Gestation Age: A Potential Role of FPR2 in the Regulation of Epithelial-Mesenchymal Transition
por: Murthi, Padma, et al.
Publicado: (2020)

Application of small molecule FPR1 antagonists in the treatment of cancers
por: Ahmet, Djevdet S., et al.
Publicado: (2020)

FPR1 mediates the tumorigenicity of human cervical cancer cells
por: Cao, Guangming, et al.
Publicado: (2018)

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
por: Castoldi, Francesca, et al.
Publicado: (2018)

Ferroptosis in infection, inflammation, and immunity
por: Chen, Xin, et al.
Publicado: (2021)

TET2, an “ambiguous” player in inflammation
por: Espinosa-Oliva, Ana María, et al.
Publicado: (2020)

Molecular Structure, Expression and Role of TAFA4 and its Receptor FPR1 in the Spinal Cord
por: Zhu, Sipin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8l8jb1e4rs2c5t2rq67ja5joqa